GlassScriptPhysician profile
Emily C Hughes
NPI 1750799300
$7,525.84
in general payments reported to CMS, 2019-2025
25 companies · $394 in 2025
The $394 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,161 · 2022: $2,122 · 2023: $1,626 · 2024: $1,222 · 2025: $394.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,703 · Travel and Lodging: $1,539.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,703.38 |
| Travel and Lodging | $1,539.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $3,422.52 | 2021-2024 | Prodigy, Proclaim, Eterna |
| Spinal Simplicity, LLC | $1,396.61 | 2022-2024 | Ha Minuteman G3-R |
| Boston Scientific Corporation | $1,167.85 | 2021-2025 | Intracept, General - Pain Management, Wavewriter Alpha Prime 16 |
| Abbvie INC. | $315.40 | 2021-2025 | |
| Medtronic, INC. | $281.15 | 2021-2025 | Vanta Adaptivestim, Intellis Adaptivestim, Kyphon Express II Kyphopak Tray |
| Relievant Medsystems, INC. | $269.40 | 2021-2023 | Intracept |
| Amgen INC. | $124.15 | 2021-2022 | |
| Mml US, INC. | $78.12 | 2025 | Reactiv8 |
| Collegium Pharmaceutical, INC. | $71.99 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $53.06 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $45.36 | 2022 | |
| Pfizer INC. | $31.99 | 2021-2023 | |
| Pacira Pharmaceuticals Incorporated | $29.31 | 2023 | Zilretta, Iovera, Exparel |
| Grt US Holding, INC. | $29.06 | 2021-2022 | |
| Globus Medical, INC. | $26.92 | 2025 | Vyrsa V1 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $24.09 | 2021 | |
| Allergan, INC. | $23.87 | 2021 | |
| Galderma Laboratories, L.P. | $22.38 | 2024 | Dysport |
| Vertos Medical, INC. | $21.42 | 2024 | Mild Device Kit |
| Lundbeck LLC | $21.09 | 2025 | Vyepti |
| Vertex Pharmaceuticals Incorporated | $17.81 | 2024 | |
| Nalu Medical, INC. | $14.07 | 2025 | Nalu Neurostimulation System |
| Curonix LLC | $13.78 | 2025 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| Fidia Pharma USA INC. | $13.13 | 2021 | |
| Lilly USA, LLC | $11.31 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Emily Hughes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.